Oral hypoglycemic drugs: An overview
The aim of this study was to evaluate safety and efficacy of oral hypoglycemic agents in obese Type-2 diabetic patients. The objectives are to compare fasting and postprandial blood sugar (PPBS) levels, to compare body mass index in all the groups and to identify glycosylated hemoglobin levels and adverse drug reaction in all the groups. Diabetes mellitus is one of the world’s major diseases. It currently affects an estimated143 million people worldwide and the number is growing rapidly. In the India, about 1-5% population suffer from diabetes or related complication. So there is need to cure this disease. Anti-diabetic drugs treat diabetes mellitus by lowering glucose levels in the blood. With the exceptions of insulin, exenatide, and pramlintide, all are administered orally and are thus also called oral hypoglycemic agents or oral anti hyperglycemic agents. There are different classes of anti-diabetic drugs, and their selection depends on the nature of the diabetes, age and situation of the person, as well as other factors. Diabetes mellitus type 1 is a disease caused by the lack of insulin. Insulin must be used in Type 1, which must be injected or inhaled. Diabetes mellitus type 2 is a disease of insulin resistance by cells. Treatments include agents which increase the amount of insulin secreted by the pancreas, agents which increase the sensitivity of target organs to insulin , and agents which decrease the rate at which glucose is absorbed from the gastrointestinal tract.
Keywords: hypoglycemic, blood suger, insulin, diabetes mellitus, pancreas
2. Hollander P. Anti-diabetes and anti-obesity medications: Effects on weight in people with diabetes. Diabetes Spectrum 2007; 20:159-65.
3. Golay A, Ybarra J. Link between obesity and Type 2 diabetes. Best Pract Res Clin Endocrinol Metab 2005; 19:649-63.
4. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med. 2003; 115 Suppl 8A:42S-8.
5 WHO Expert Committee on Diabe tes Mellitus. Second Report. Geneva: WHO, 1980.Technical Report Series 646.
6. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:0183–97.
7.Domecq JP, Prutsky G, Leppin A, et al. Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015; 100:363-70.
8. Malaisse WJ. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Horm Metab Res 1995; 27: 263-6.
9. Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23:1660-5.
10. Bellomo Damato, A., et al., Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia. Diabet Med, 2011; 28(5):560-566.
11. Bailey CJ, Turner RC. Metformin. N Eng J Med 1996; 334:574-579.
12. Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 2012; 125:302.e1-7.
13. Cusi K, De Fronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev 1999; 6:89-130.
14. Eldor R, Raz I. Diabetes therapy--focus on Asia: second-line therapy debate: insulin/secretagogues. Diabetes Metab Res Rev 2012; 28 Suppl 2:85-9.
15. Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia 2013; 56:973-84.
16. Forst T, Hanefeld M, Jacob S, Moeser G, Schwenk G, Pfützner A, et al. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res 2013; 10:302-14
17. Ryan EH Jr, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina 2006; 26(5):562–70
18. Deacon CF. DPPIV and diabetes. Clin Chem Lab Med 2008; 46:A18.
19. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3:153‑65.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).